Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.
加州圣马特奥，2024年9月5日 /环球新闻社/ - Talphera公司(Nasdaq: TLPH)（"Talphera"）是一家专注于开发和商业化创新治疗方案，用于医疗监督环境中的特殊药品公司，今天宣布管理层将参加H.C. Wainwright第26届全球投资大会，并将进行1x1会议。
The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors section of the Company's website at and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section.
该大会将于2024年9月9日至11日在纽约市Lotte New York Palace酒店举行，演示将于9月9日上午7:00在此处按需提供，或者通过访问公司网站的投资者部分，点击投资者/新闻与事件/即将举行的活动中发布的网络广播链接。
About Talphera, Inc.
关于Talphera公司
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
Talphera公司是一家专注于开发和商业化创新治疗方案，用于医疗监督环境中的特殊药品公司。Talphera的主力产品Niyad是一种凝固酶的冻干制剂，目前正在作为体外循环抗凝剂进行调查设备豁免(IDE)研究，并已获得美国食品和药物管理局(FDA)的突破性设备认定地位。
This release is intended for investors only. For additional information about Talphera, please visit .
此公告仅针对投资者。有关Talphera的其他信息，请访问。
SOURCE Talphera, Inc.
资讯来源：Talphera公司。
